Investigators reported the prespecified 5-year analysis of RELATIVITY-047 with a minimum follow-up of 57.3 months. The combination of relatlimab plus nivolumab continued to separate from nivolumab alone across survival curves. For the primary endpoint, progression-free survival (PFS), the study team observed a hazard ratio of 0.77 (95% confidence interval: 0.65–0.92) favoring the combination. The cohort showed an overall survival (OS) benefit as well; data indicated a hazard ratio of 0.78 (95% confidence interval: 0.64–0.95). Melanoma-specific survival (MSS) also favored the combination with a reported hazard ratio of 0.71 (95% confidence interval: 0.57–0.88). These numerical effect sizes were presented in the source as the largest absolute differences reported to date for this trial across PFS, OS and MSS.
Short-term responses were part of the secondary endpoints, and the authors noted continued clinically meaningful differences by treatment arm. The source did not provide further breakdowns of response rates, duration of response, or landmark survival percentages in the abstract-level text available here; those details may appear in the full paper or Version of Record.
The study team reported that the safety profile at 5 years remained consistent with prior reports from RELATIVITY-047. No new long-term safety signals were described in the abstract. The source did not list specific adverse event incidences, grade distributions, or treatment discontinuation rates in this early-release version. Because long-term toxicity and survivorship issues determine clinical utility for immune combinations, readers should consult the full publication for detailed safety tables and organ-specific adverse event patterns when the final Version of Record is published.
The authors performed exploratory biomarker analyses, including subgrouping by programmed death ligand 1 (PD-L1) expression. Among biomarker-evaluable patients with PD-L1 ≥1%, analyses indicated that high levels of peripheral or tumor LAG-3+ CD8 cells were associated with worse outcomes on nivolumab monotherapy. The cohort showed a lower prevalence of primary resistance when treated with the combination compared with nivolumab alone, a signal the investigators interpreted as evidence that relatlimab can counteract LAG-3–mediated resistance to PD-1 blockade.
These biomarker observations separated patterns that the authors linked to primary versus acquired resistance states. The report presented these findings as hypothesis-generating and exploratory. The source did not include full methodological details for the biomarker assays, thresholds used to define “high” LAG-3+ CD8 levels, or the exact numbers of patients in each biomarker subgroup within the abstract text provided here. Readers should refer to the complete manuscript for assay methods, predefined cutoffs, and subgroup sample sizes.
RELATIVITY-047 is a phase 2–3, double-blind randomized trial in metastatic or unresectable melanoma. Patients were randomized 1:1 to intravenous nivolumab 480 mg plus relatlimab 160 mg every 4 weeks (n = 355) or nivolumab 480 mg every 4 weeks (n = 359). The primary endpoint was PFS per blinded independent central review; secondary endpoints included OS, response and safety. Additional post-hoc analyses described in the source included MSS and exploratory biomarker assessments.
The source stated that this version of the article is an early, peer-reviewed accepted manuscript and that it will be replaced by the final Version of Record. The minimum follow-up for this analysis was 57.3 months. The abstract did not report subsequent lines of therapy, crossover rates, or treatment exposure durations beyond the dosing schedule noted above; such details are required for granular interpretation of long-term survival data and will presumably appear in the final publication.
The source text supplied here did not enumerate formal study limitations or list regulatory next steps. The authors characterized biomarker analyses as exploratory and post-hoc where applicable; this implies hypothesis-generating findings rather than definitive predictive biomarkers. The abstract did not provide assay cutoffs, subgroup sample sizes for biomarker-evaluable populations, or detailed adverse-event tables. The early-release status of the manuscript means readers should expect further edits and expanded methods and results in the Version of Record. Specific unanswered clinical questions—such as how these biomarker signals perform prospectively, the magnitude of benefit in defined PD-L1 or LAG-3 strata, and real-world tolerability over longer survivorship—were not resolved in this source and were not reported in the abstract.
ClinicalTrials.gov identifier for RELATIVITY-047 is NCT03470922. For clinicians and researchers seeking to apply these findings to practice or to design subsequent studies, the next step is to consult the full published record when the Version of Record is available, which will include the complete safety tables, biomarker methods, subgroup sizes and any additional analyses not present in this early version.